Ashrafuzzaman Md. Ji, Su Hyun Ahn, Hyomin Chung, Hwan Won Choi, Daeun Park, Ju Jin Go, Min Ji Pyo, Jung in Azam Sharif Mohammed Shafioul Lee, Duck­Hyung Chi, Sung­Gil Song, Chiman Cheong, Chan Seong Han, Seojung 2024-01-12T06:35:27Z 2024-01-12T06:35:27Z 2023-04-05 2023-07 0253-2964 https://pubs.kist.re.kr/handle/201004/79895 Novel 1-phenoxy-3-(piperazin-1-yl)propan-2-ol derivatives were designed and synthesized as potential triple reuptake inhibitors, which simultaneously inhibit serotonin, norepinephrine, and dopamine transporters (SERT, NET, and DAT, respectively). Through neurotransmitter transporter uptake assays, inhibitory activities of 1-phenoxy-3-(piperazin-1-yl)propan-2-ol derivatives were evaluated. We discovered compound 19 exhibited the most potent inhibitory activities against all three monoamine neurotransmitter transporters and the IC50 values of 19 against SERT, NET, and DAT were determined. In addition, binding modes of 19 with SERT, NET, and DAT were predicted by docking studies. English 대한화학회 Identification of 1-phenoxy-3-(piperazin-1-yl)propan-2-ol derivatives as novel triple reuptake inhibitors Article 10.1002/bkcs.12693 1 Bulletin of the Korean Chemical Society, v.44, no.7, pp.596 - 599 Bulletin of the Korean Chemical Society 44 7 596 599 N scie scopus kci ART002981861 000960626800001 Chemistry, Multidisciplinary Chemistry Article antidepressants aryloxypropanolpiperazine major depressive disorder monoamine neurotransmitter triple reuptake inhibitor